Nonalcoholic Fatty Liver Disease. Liver disorders in diseases classified elsewhere
Conditions
Interventions
Intervention 1: Intervention group: Sumac powder capsule + diet. Intervention 2: Control group: Medicinal starch capsule + diet.
Sponsors
Shiraz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to 60 Years
Inclusion criteria
Inclusion criteria: Desire to participate in study Male or female 20-60 years old Patient who diagnosed NAFLD with using ultrasound by physician The power of decision making and the ability to do life without the help of others BMI : 25- 35
Exclusion criteria
Exclusion criteria: No history of alcohol using No history of liver cirrhosis Lack of other chronic and acute liver disorders (hepatitis B, C, etc.) and effective hereditary diseases, cancers and hereditary infections affecting the liver (iron storage disease, copper, etc.) Lack of using of blood lipids, blood sugar, vitamin E and UDCA and hepatotoxic drugs such as phenytoin, amoxifen and lithium Lack of celiac disease, diabetes, cardiovascular disease, pulmonary and kidney disease, no history of thyroid problems No history of weight loss surgery, no recent weight loss plan in 3 months Lack of supplementation of fiber, omega-3 and antioxidants in 3 months ago
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Alanine aminotransferase (ALT) enzyme. Timepoint: Baseline and the end of the intervention. Method of measurement: ALT kit.;Aspartate aminotransferase (AST) enzyme. Timepoint: Baseline and the end of the intervention. Method of measurement: AST kit.;Weight. Timepoint: Baseline and the end of the intervention. Method of measurement: scale/ kg.;Cholestrol. Timepoint: Baseline and the end of the intervention. Method of measurement: Cholestrol Kit.;Triglyceride. Timepoint: Baseline and the end of the intervention. Method of measurement: Triglyceride Kit.;Low-density lipoprotein. Timepoint: Baseline and the end of the intervention. Method of measurement: Low-density lipoprotein Kit.;High-density lipoprotein. Timepoint: Baseline and the end of the intervention. Method of measurement: High-density lipoprotein Kit.;Fasting blood suger. Timepoint: Baseline and the end of the intervention. Method of measurement: Fasting blood suger Kit.;Insulin. Timepoint: Baseline and the end of the intervention. Method of measurement: Insulin Kit.;Total Antioxidant Capacity. Timepoint: Baseline and the end of the intervention. Method of measurement: Total Antioxidant Capacity Kit.;Tumor Necrosis Factor alpha. Timepoint: Baseline and the end of the intervention. Method of measurement: Tumor Necrosis Factor alpha Kit.;Alkaline Phosphatase. Timepoint: Baseline and the end of the intervention. Method of measurement: Alkaline Phosphatase kit.;Height. Timepoint: Baseline and the end of the intervention. Method of measurement: Meter.;Waist circumference. Timepoint: Baseline and the end of the intervention. Method of measurement: Meter.;Hip circumference. Timepoint: Baseline and the end of the intervention. Method of measurement: Meter.;Fat mass. Timepoint: Baseline and the end of the intervention. Method of measurement: BIA device.;Fat Free mass. Timepoint: Baseline and the end of the intervention. Method of measurement: BIA device.;Total Body Water. Timepoint: Baseline and the end of the interv | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohsen Mohit
Shiraz University of Medical Sciences
Outcome results
None listed